Sandoz, a global leader in generic and biosimilar medicines, announced that the European Commission (EC) granted marketing authorization for the first and only biosimilar Tyruko (natalizumab), developed by… read more.
Attention-deficit/hyperactivity disorder (ADHD) is among the most common pediatric neurodevelopmental disorders. In 2019, nearly 10% of United States (U.S.) children had a diagnosis of ADHD. Approximately 3.3 million… read more.
On 14 September 2023, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product… read more.
A new approach to electrically stimulating the brain can improve the gait of people with Parkinson’s disease (PD), according to a study by Shinshu University in Japan. The… read more.
People exposed to night shifts and rotating shift work are more likely to experience cognitive impairment in later life, according to a new study from York University, Canada…. read more.
European medicines regulators are studying the potential risk of neurodevelopmental disorders (NDDs) in children conceived by fathers taking valproate, an epilepsy medicine. Preliminary data suggest a possible association… read more.
New research published in the Journal of the American Geriatrics Society indicates that antipsychotics are likely overprescribed and used inappropriately among patients with Alzheimer’s disease and related dementias (ADRD) receiving… read more.
Sandoz, a global leader in generic and biosimilar medicines, announced that the FDA has approved its biosimilar Tyruko (natalizumab-sztn), developed by Polpharma Biologics. Tyruko is approved to treat… read more.
Patients who have suffered an intracerebral hemorrhage (bleeding stroke) who subsequently take statins appear to have a lower risk of having another stroke, especially an ischemic stroke, when… read more.
Researchers from a newly published study report that, among patients with atrial fibrillation, the risk of developing dementia among those who underwent catheter ablation was about half that… read more.
Multiple studies have demonstrated the memory-enhancing effects of melatonin and its derivatives in animal models. It is also known that the formation of both short- and long-term memories… read more.
AbbVie announced that the European Commission has approved Aquipta (atogepant) for the prophylaxis of migraine in adults who have four or more migraine days per month. The approval… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
